Trials / Recruiting
RecruitingNCT07313176
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
A Prospective, Non-Interventional Study on the Long-term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIGON®) in Patients With Parkinson's Disease Previously Treated With Subcutaneous Foslevodopa in Routine Care
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 215 (estimated)
- Sponsor
- Britannia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part IV (MDS-UPDRS IV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | This is a non-interventional study. |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2028-10-01
- Completion
- 2029-01-01
- First posted
- 2025-12-31
- Last updated
- 2026-01-21
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT07313176. Inclusion in this directory is not an endorsement.